By Mariam Sunny Jan 13 (Reuters) - The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, ...
US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased risk of suicidal thoughts or behaviour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results